A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Phase 2
Completed
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Registration Number
- NCT00002169
- Lead Sponsor
- Agouron Pharmaceuticals
- Brief Summary
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Univ of Southern California / LA County USC Med Cntr
🇺🇸Los Angeles, California, United States
Univ of California / UCI Med Ctr
🇺🇸Orange, California, United States
Univ of California / San Diego Treatment Ctr
🇺🇸San Diego, California, United States
Harbor UCLA Med Ctr
🇺🇸Torrance, California, United States
George Washington Univ
🇺🇸Washington, District of Columbia, United States
Northwestern Univ / SOCA
🇺🇸Chicago, Illinois, United States
Univ of Texas Med Branch
🇺🇸Galveston, Texas, United States
Baylor Univ
🇺🇸Houston, Texas, United States
Univ of Southern California / LA County USC Med Cntr🇺🇸Los Angeles, California, United States